GlassScriptPhysician profile
Abhinav Rohatgi
NPI 1073990107
$2,401.86
in general payments reported to CMS, 2019-2025
24 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $244 · 2021: $513 · 2022: $99.00 · 2023: $246 · 2024: $339 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.71 |
| Education | $161.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $276.94 | 2021-2023 | |
| Janssen Biotech, INC. | $258.71 | 2019-2024 | Darzalex |
| Amgen INC. | $243.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $210.23 | 2020-2025 | Fasenra |
| Abbvie INC. | $197.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $157.49 | 2023-2024 | Pomalyst, Krazati |
| Novartis Pharmaceuticals Corporation | $149.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $127.63 | 2024-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $102.51 | 2019 | |
| Genentech USA, INC. | $75.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $72.00 | 2019 | |
| Celgene Corporation | $70.88 | 2024 | Reblozyl |
| Menarini Silicon Biosystems, INC. | $68.86 | 2024-2025 | |
| Pfizer INC. | $50.37 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.55 | 2020 | |
| Spectrum Pharmaceuticals INC. | $35.61 | 2025 | Rolvedon |
| Beigene USA, INC. | $34.52 | 2023 | Brukinsa |
| Springworks Therapeutics, INC. | $27.71 | 2025 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $22.06 | 2025 | Monoferric |
| Geron Corporation | $15.69 | 2025 | Rytelo |
| Emd Serono, INC. | $14.75 | 2023 | Tepmetko |
| Genzyme Corporation | $14.53 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhinav Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.